Lundbeck U-turn in execution drug row

danmand

Well-known member
Nov 28, 2003
46,971
5,606
113
Lundbeck U-turn in execution drug row

Published 08.06.11 14:50

Company promises to investigate ways to prevent American prisons using their epilepsy drug to kill prisoners.

Unwitting execution drug manufacturer Lundbeck met with human rights organisation Reprieve this week to discuss ways to prevent its anti-epilepsy being used on America’s death-row.

In March, The Copenhagen Post reported that Lundbeck felt there was nothing it could do to prevent American prisons using its drug Nembutal in lethal injections.

“We have been looking into the problem and there’s nothing that we can do to control where the product ends up,” a representative from Lundbeck told the paper at the time.

But this Monday, three months after the company dismissed forcing distributors to sign ‘end user agreements’ to prevent the drug being sold to prisons, chief executive Ulf Wiinberg met with Reprieve to discuss its options.

“We have of course continued our efforts to solve this problem, on how to make the states stop this misuse of our medicine by writing and contacting and contacting the prisons in question,” said Lundbeck representative Mads Kronborg.

“Reprieve has highlighted the possibilities in terms of restricting distribution by making it harder for prisons to get the drug while keeping a supply for hospitals to get the drugs to treat patients with severe epilepsy.

“We want to do this right so we are starting an investigation to see how we can restrict the distribution. But it must be noted that it will not necessarily be 100 percent certain to prevent the prisons getting hold of the drugs.”

Reprive’s Maya Foa stressed that their meeting with Lundbeck’s demonstrated they were moving in the right direction.

“They have changed their position which is good and are acknowledging that there are ways to restrict their product. So now they are looking for the most effective solution,” she said to The Copenhagen Post.

“We discussed some strategies and they are now going to tell us more specifically what they can do to restrict the sole of the product within the next two weeks.”

Lundbeck’s handling of the case has been widely criticised by human rights organisations and in the media since it was revealed in February that some American states were considering using their product to execute prisoners.

Nembutal, generically known as pentobarbital, is widely used in the US as an anti-epileptic medication, but is now being used by correctional authorities in seven states to execute prisoners after exports from Europe of their first-choice drug, sodium thiopental, were stopped in protest.

So far 13 prisoners have been executed using the drug despite warnings by health experts that it may not be effective or humane.

In May, Danish pension fund Unipension sold 40 million kroner of Lundbeck shares partially in response to Lundbeck’s handling of the case.

“Our immediate assessment is that Lundbeck does not violate our guidelines. But we think their handling of the matter has been inappropriate,” said Unipension chief investor Niels Erik Petersen in a press release.

The company’s criticism, Petersen continued, concerned “both Lundbeck’s opacity towards the public and the company’s lack of willingness to enter into dialogue with investors. It has not been possible for instance to receive a detailed account of Lundbeck’s efforts to best prevent their products being used in an unwanted way”.

But Foa from Reprieve said she thought Lundbeck had learned its lesson.

“They got a lot of criticism for not talking openly enough and they’ve recognised that. Now they are going to make everything more transparent and produce something that can be published,” she said.

Lundbeck is now looking at options such as the previously dismissed ‘end user agreements’, which would prevent distributors supplying prisons with the drugs.

“We have now realised that even though we can’t be completely certain where the drugs end up we should work towards making it harder for the prisons to get the drugs,” said Lundbeck spokesperson Kronborg.

“Nobody wants to end this misuse more than us.”